DMIC
AZN icon

Dixon Mitchell Investment Counsel’s AstraZeneca AZN Stock Holding History

Dixon Mitchell Investment Counsel’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152K Sell
804
-402
-33% -$75.6K 0.01% 85
2026
Q1 		$238K Buy
+1,206
New +$233K 0.01% 73
2024
Q3 		– Sell
-14
Closed -$2.11K – 99
2024
Q2 		$2.11K Buy
+14
New +$2.11K ﹤0.01% 141

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dixon Mitchell Investment Counsel's AZN Position: Q2 2026 in Review

Dixon Mitchell Investment Counsel reduced its AstraZeneca (AZN) stake by 33% in Q2 2026, selling an estimated $75.6K and leaving 804 shares worth $152K. The position accounts for 0.01% of the portfolio, ranked #85.

Dixon Mitchell Investment Counsel first reported a position in AZN in Q2 2024 and has held it in 3 quarters since. The position peaked at $238K in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Dixon Mitchell Investment Counsel held 804 shares of AstraZeneca worth $152K as of Q2 2026.
  • Dixon Mitchell Investment Counsel sold 402 AstraZeneca shares in Q2 2026, an estimated $75.6K.
  • AstraZeneca made up 0.01% of Dixon Mitchell Investment Counsel's portfolio in Q2 2026, its #85 holding.
  • Dixon Mitchell Investment Counsel first reported a position in AstraZeneca in Q2 2024 and has held it in 3 quarters since.
  • Dixon Mitchell Investment Counsel's AstraZeneca position peaked at $238K in Q1 2026.
  • 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Dixon Mitchell Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.